| Objective: To research the risk factors of the cardiotoxicity of chemotherapy with anthracycline in patients with breast cancer, and compare the cardiotoxicity of pirarubicin with epirubicin. Method: A total of 186 patients were divided into pirarubicin group and pirubicin group randomly. All patients, who were confirmed to be breast cancer by pathology, had no angiocardiopathy and their test in ECG, myocardial enzyme and cTnI were normal before the operation. At the same time, their tumor have not been transferred to other organs. Two adjuvant chemotherapy initiated on the 7th day after operation. Patients in the pirarubicin group received threeweekly concurrent cytoxan, pirarubicin and 5-fluorouracil for 6 cycles. The ones in the epirubicin group received threeweekly concurrent cytoxan, epirubicin and 5-fluorouracil for 6 cycles. Recorded the chang of ECG, myocardial enzyme and cTnI in the two group after chemotherapy. Results: The difference of cardiotoxicity between different nationalities is not significant(P>0.05), neither in the different stages(P>0.05). However, the difference of cardiotoxicity between different ages is significant(P<0.05), and it is significant in different therapies either(P<0.05). 42 patients with abnormal ECG, myocardial enzyme or cTnI in the pirarubicin group were found out and 57 patients in the epirubicin group, and the difference is significant(P<0.05). Conclusions: The difference of different nationalities and stages are not the risk factor of the cardiotoxicity of chemotherapy with anthracycline in patients with breast cancer, and different drugs, age and radiotherapy are the risk factors. Epirubicin has more cardiotoxicity than pirarubicin. |
PDF Full Text Request